News & Updates

Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the final analysis of the NORA trial presented at SGO 2024.

A minimally invasive approach to interval debulking surgery appears to be just as effective as the use of an open technique for epithelial ovarian cancer, with no significant difference in overall survival (OS) when complete tumour resection is achieved, according to a study.

A novel device that integrates hexaminolevulinate (HAL) hydrochloride (HCl) with photodynamic therapy for the treatment of cervical histologic high-grade squamous intraepithelial lesions (HSIL) has shown good results in the global phase III APRICITY study, with lasting efficacy and an acceptable safety profile.

Maternal supplementation with vitamin B12 provides benefits on both short- and long-term human milk (HM) status, as shown in a study.

Adding pembrolizumab to standard chemotherapy resulted in a favourable overall survival (OS) benefit in patients with advanced or recurrent endometrial cancer compared with chemotherapy alone, regardless of mismatch repair (MMR) status, according to a key prespecified secondary analysis of the NRG-GY018 trial presented at the SGO 2024.

Pregnant women who are being treated with ustekinumab or vedolizumab appear to experience no greater complications as those receiving antitumour necrosis factor (anti-TNF) agents, immunomodulators, or combination anti-TNF/immunomodulators, according to a study.

A device that combines radiofrequency (RF) with pulsed electromagnetic field–based device (PEMF) appears safe to use and has been shown to improve symptoms related to vulvovaginal atrophy (VVA) as well as female sexual function, reports a study. In addition, the nonablative, noncoagulative multipolar RF/PEMF device yields high satisfaction from women.

New drug applications approved by US FDA as of 1-15 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.